 This is a multicenter retrospective comparison of 2 myeloablative conditioning regimens in 454 patients with acute myeloid leukemia in remission busulfan and fludarabine versus thiotepa busulfan and fludarabine . Eligible for this study were patients allografted between January 2008 and December 2018 in 10 transplant centers with AML in first or second remission 201 patients received BUFLU whereas 253 received TBF . The 2 groups were comparable for age

@highlight The combination of thiotepa and busulfan fludarabine reduces the risk of relapse in patients with remission acute myeloid leukemia compared with myeloablative busulfan fludarabine.
@highlight The effect is independent of donor type and graft versus host disease prophylaxis.
